Founded in 2015, Beta Bionics develops and commercializes medical technologies designed to improve the quality of life for people with diabetes. The company's primary offering, the iLet Bionic Pancreas, is an FDA-cleared wearable device that pairs with continuous glucose monitors to automate insulin delivery for individuals with type 1 diabetes. Beta Bionics manufactures the iLet system and its ready-to-fill insulin cartridges at its facilities in California. The company is also developing a pipeline of future innovations, including a tubeless patch pump and a bihormonal system designed to deliver both insulin and a glucagon analog to further reduce the risk of hypoglycemia. By focusing on simplifying diabetes management and reducing the cognitive burden on patients, Beta Bionics competes in the rapidly growing automated insulin delivery market.
